Calnexin antibody [N3C2], Internal
|Applications||ICC/IF, IHC-P, WB|
Not tested in other applications.
|IHC (Formalin-fixed paraffin-embedded sections)||1:100-1:1000*
*Optimal dilutions/concentrations should be determined by the researcher.
|Predicted Target Size||68 kDa (note)
|Positive Controls||293T , A431 , H1299 , HeLaS3 , HepG2 , Molt-4 , Raji , NIH-3T3 , PC-12 , Rat2|
(Please refer to the vial label for the specific concentration)|
|Purification||Purified by antigen-affinity chromatography.|
|Product Description||Rabbit Polyclonal antibody to Calnexin (calnexin)|
|Background||This gene encodes a member of the calnexin family of molecular chaperones. The encoded protein is a calcium-binding, endoplasmic reticulum (ER)-associated protein that interacts transiently with newly synthesized N-linked glycoproteins, facilitating protein folding and assembly. It may also play a central role in the quality control of protein folding by retaining incorrectly folded protein subunits within the ER for degradation. Alternatively spliced transcript variants encoding the same protein have been described. [provided by RefSeq]|
|Synonyms||CNX antibody, FLJ26570 antibody, IP90 antibody, P90 antibody, CANX antibody, major histocompatibility complex class I antigen-binding protein p88 antibody, calnexin antibody|
|Cellular Localization||Endoplasmic reticulum membrane , Melanosome |
|Immunogen||Recombinant protein encompassing a sequence within the center region of human Calnexin. The exact sequence is proprietary.|
|Species Reactivity||Human, Mouse, Rat|
|Predicted Cross Reactivity species Predicted cross-reactivity:|
Predicted cross-reactivity is based on sequence homology, with greater than 80% immunogen sequence identity considered positive.
Please note that we are only able to guarantee products to work in applications and species in which they have been tested.
|Zebrafish, Xenopus laevis, Dog, Pig, Chicken, Bovine|
|Predict Reactivity Note||Zebrafish (82%), Xenopus laevis (89%), Dog (94%), Pig (94%), Chicken (91%), Bovine (94%)|